LIVE MARKET TRACKER :   BSE SENSEX   31599.76      |    NSE NIFTY 9871.50    
GLOBAL MARKETS :  NASDAQ 6370.5898   -0.8765%    |    FSI London 7303.03   +0.02%    |    NIKKEI Japan 20330.19   -0.33%
  USD GBP EUR CAD AUD INR
USD - 0.7447 0.8486 1.2379 1.2675 65.6000
GBP 1.3430 - 1.1394 1.6624 1.7022 88.1162
EUR 1.1790 0.8777 - 1.4591 1.4939 77.3174
CAD 0.8084 0.6023 0.6858 - 1.0246 53.0270
AUD 0.7890 0.5877 0.6695 0.9768 - 51.7590
INR 0.0153 0.0114 0.0129 0.0189 0.0194 -
Indian-Commodity  :  Equity & Shares  :  Lupin trades higher on the bourses

Lupin trades higher on the bourses (07-Jul-2017)

Lupin is currently trading at Rs. 1128.70, up by 47.45 points or 4.39% from its previous closing of Rs. 1081.25 on the BSE.

The scrip opened at Rs. 1089.70 and has touched a high and low of Rs. 1132.45 and Rs. 1085.00 respectively. So far 1,54,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1750.00 on 29-Jul-2016 and a 52 week low of Rs. 1036.80 on 05-Jul-2017.

Last one week high and low of the scrip stood at Rs. 1132.45 and Rs. 1036.80 respectively. The current market cap of the company is Rs. 50,999.00 crore.

The promoters holding in the company stood at 46.69%, while Institutions and Non-Institutions held 41.24% and 12.06% respectively.

Pharma Major Lupin has launched its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base) having received an approval from the United States Food and Drug Administration (USFDA) earlier.

Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.'s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms. Vigamox Ophthalmic solution had US sales of $267.9 million as per IMS MAT March 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Top News Today
Jaiprakash Associates gets nod to raise up to Rs 2,000 crore
(26-Sep-2017)

Jaiprakash Associates gets nod to raise up to Rs 2,000 croreJaiprakash Associates has received its shareholders' approval to raise up to Rs 2,000 crore through sale of securities. The special resolution was approved by the shareholders at the company's annual general......click on news to read complete article.

Panacea Biotec planning to raise Rs 250 crore
(26-Sep-2017)

Panacea Biotec planning to raise Rs 250 crorePanacea Biotec is planning to raise Rs 250 crore by way of issue of equity shares and/or other securities. In this regards, the company is conducting Postal Ballot for obtaining approval of members for......click on news to read complete article.

Novartis India gets nod for Rs 231.15 crore buyback plan
(26-Sep-2017)

Novartis India gets nod for Rs 231.15 crore buyback planNovartis India has received an approval for buyback of up to 34.5 lakh shares, accounting for about 12.26% of the existing paid up capital of the company, for up to Rs 231.15 crore. The company's board......click on news to read complete article.

International Stock News
Asian markets trade mostly lower in early deals on Tuesday
(26-Sep-2017)

Asian markets trade mostly lower in early deals on TuesdayMost of the Asian equity benchmarks are trading down in the early deals on Tuesday, following declines on Wall Street overnight, as the war of words between North Korea and the US escalated. Meanwhile,......click on news to read complete article.

US markets closed lower on North Korea's threat
(26-Sep-2017)

US markets closed lower on North KoreaThe US markets closed lower on Monday, on the back of a fresh flare up in tensions between the US and North Korea and a sharp decline in technology shares. North Korean foreign minister Ri Yong Ho, speaking......click on news to read complete article.

Asian markets trade mostly lower in early deals on Monday
(25-Sep-2017)

Asian markets trade mostly lower in early deals on MondayMost of the Asian equity benchmarks are trading down in the early deals on Monday, following the lackluster cues from Wall Street and concerns about China's economy. Investors digested election results......click on news to read complete article.

 

     
  
Recent Equity & Shares News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.